{
  "docId": "019dd923-622c-750b-8b9b-c622cb82b5b7",
  "docSlug": "62936067f4f8",
  "documentTitle": "Pershing Square Holdings Portfolio (multi-position) (PSH)",
  "authorId": "01_Pershing_Square",
  "authorName": "William Ackman",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2017-01-26 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 73,
  "pageCount": 95,
  "prevPage": 72,
  "nextPage": 74,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "Slide 73 from a Pershing Square activist deck regarding Valeant Pharmaceuticals.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "bullet_list"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9b-c622cb82b5b7/73",
  "deckHref": "/decks/019dd923-622c-750b-8b9b-c622cb82b5b7",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9b-c622cb82b5b7.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-c622cb82b5b7#slide-73",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.85,
        "x": 0.04,
        "y": 0.85
      },
      "kind": "callout",
      "text": "Despite significant operational progress throughout the year creating the “New Valeant,” share price performance continues to disappoint",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd436640-3ae7-4c22-ad3b-f9ccefdef2d8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.85,
        "x": 0.08,
        "y": 0.35
      },
      "kind": "list",
      "text": "Refreshed Board of Directors; Built new leadership team around new CEO Joe Papa; Launched asset sale program; Announced transactions to generate ~$2.35bn in proceeds; Improved transparency; Refocused business; Continued R&D; Formed Patient Access Committee",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6263b7ee-3336-4c08-83f0-93bac1c6e77d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.04,
        "y": 0.29
      },
      "kind": "paragraph",
      "text": "Valeant has achieved significant tangible progress over the course of the year:",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "799afdb5-3f8d-4319-a4e3-2e4b497bd5b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.16
      },
      "kind": "paragraph",
      "text": "Following a substantial decline in Valeant’s share price in Q1 2016, Bill Ackman and Steve Fraidin joined Valeant’s Board of Directors in March 2016 as part of Pershing Square’s effort to stabilize the company and protect our investment",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9b2936f1-62c2-49c0-96b5-33024ca7e40e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.04,
        "y": 0.08
      },
      "kind": "title",
      "text": "2016: Creating the New Valeant",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "94ec5a83-705f-49f7-950e-2af61d361f6c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 95,
      "from": 15,
      "beatId": "4730cd1b-0114-4ab3-afd3-5c0e7aee6451",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The document provides a comprehensive update on the fund's current portfolio, highlighting progress and positive returns.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}